

**AD-A272 682**



AD \_\_\_\_\_

2

MIPR NO: 93MM3505

**TITLE: GROWTH DYNAMICS OF BREAST CANCER CELLS: A STUDY OF GROWTH REGULATORY FACTORS**

**PRINCIPAL INVESTIGATOR: Bruce C. Veit, Ph.D.**

**CONTRACTING ORGANIZATION: William Beaumont Army Medical Center  
Department of Clinical Investigations  
El Paso, Texas 79920-5001**

**REPORT DATE: October 12, 1993**

**TYPE OF REPORT: Midterm Report**

**S DTIC  
ELECTE  
NOV 16 1993  
A**

**PREPARED FOR: U.S. Army Medical Research and  
Development Command, Fort Detrick  
Frederick, Maryland 21702-5012**

**DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited**

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**93-27816**



93 11 10 107

3145

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 12 October 1993	3. REPORT TYPE AND DATES COVERED Midterm Report (10/21/92-9/30/93)	
4. TITLE AND SUBTITLE Growth Dynamics of Breast Cancer Cells: A Study of Growth Regulatory Factors			5. FUNDING NUMBERS MIPR No. 93MM3505	
6. AUTHOR(S)  Bruce C. Veit, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) William Beaumont Army Medical Center Department of Clinical Investigations El Paso, Texas 79920-5001			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research & Development Command Fort Detrick Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words)  Due to a prolonged contracting process in the purchase of our image analysis system and to an even longer and more involved contracting process that required extensive and technically demanding justification in the purchase of our flow cytometer/cell sorter, we have been delayed almost one year in initiating our studies of breast cancer cells.				
14. SUBJECT TERMS  Breast Cancer			15. NUMBER OF PAGES	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT  Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE  Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT  Unclassified	20. LIMITATION OF ABSTRACT  Unlimited	

The contract for purchase of a flow cytometer/cell sorter was awarded to Becton-Dickinson. This instrument was installed and made operational during the first week in September 1993. The contract for purchase of an image analysis system was awarded to Roche Image Analysis Systems and the instrument was installed and made operational during the last week in August 1993. A microtome/cryostat was purchased from Zeiss Instruments Co. and was made operational in mid-September 1993.

**Scientific Progress:** Due to a prolonged contracting process in the purchase of our image analysis system and to an even longer and more involved contracting process that required extensive and technically demanding justification in the purchase of our flow cytometer/cell sorter, we have been delayed almost 1 year in initiating our studies of breast cancer cells.

At the present time, we have our flow cytometer/cell sorter in place and operational and we have our image analysis system in place and operational. Ms. Rebecca Smiley, GS-9 Microbiologist, received formal training in the operation of our flow cytometer/cell sorter at the Becton-Dickinson facility in Boston, Massachusetts in mid-September 1993. Dr. Veit, PI, and Ms. McIntyre, GS-7 Medical Technologist, received formal training in the operation of our image analysis system at the Roche Image Analysis Systems facility in Research Triangle, North Carolina during the first week in October 1993.

Several human breast cancer cell lines have been obtained from the American Type Culture Collection Company and are currently being maintained by serial passage in *in vitro* culture in our laboratory. Samples of all lines have been frozen in 10% DMSO and are being stored in our liquid nitrogen repository. These cell lines have been utilized for establishing the various staining procedures for the immunohistochemical (image analysis) and flow cytometric analyses of DNA (S-phase fraction, cell cycle, and ploidy), epidermal growth factor receptor expression and production, estrogen/progesterone receptor expression, HER-2/neu expression, Ki-67 expression, PCNA expression, transforming growth factor expression, and insulin-like growth factor expression.

Future Plans: Additional training may be required for the implementation of our DNA modeling software (Modfit) in our flow cytometric studies of DNA. Due to the delay in onset of our studies because of a prolonged contracting process in obtaining our flow cytometer/cell sorter and image analysis system, the PI will request that a no-cost extension of 18 months be granted by the contracting officer for this project (that the termination of this contract be extended from September 30, 1994 to March 31, 1996). The personnel involved in this project are fully trained (with the exception of DNA modeling training) in the operation of our flow cytometer/cell sorter and image analysis system and are currently involved in the analysis of established breast cancer cell lines and primary breast cancer biopsies with respect to growth factor requirements and/or growth factor receptor expression. *In vivo* studies, utilizing growth of breast tumors in nude mice, as well as studies of apoptosis, will be initiated within the next six months.

DTIC QUALITY INSPECTED 5

A-1	
-----	--